Skipping chemo after breast cancer surgery
Part of Cancer, Skin clinical trials.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old, and you feel well enough to do your usual activities (performance status 0-1).
- Your breast cancer is early-stage and hormone-receptor positive (ER-positive) and HER2-negative, and your lymph nodes are free of cancer.
- Your tumor is considered higher risk, such as a higher grade (grade 3) or a high Ki-67 score (20% or more) or a high-risk gene test result.
- You have not received chemotherapy, radiation, or hormone therapy before your surgery.
- Your surgery was within the last 8 weeks, and you have recovered well.
- Your blood counts, liver, and kidney function are within acceptable ranges, and you are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted pill (dalpiciclib) to standard hormone therapy can safely replace chemotherapy for women with small, hormone-positive, high-risk breast cancers.
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.